APMAdvances in Precision Medicine2424-85922424-9106WHIOCE PUBLISHING PTE. LTD.10.18063/apm.v6i2.238ArticleClinical Utility of SARS-CoV-2 Antibody Testinghttps://artdesignp.com/journal/APM/6/2/10.18063/apm.v6i2.238KimHyun Soo2021622021-07-25SARS-CoV-2 antibody assay is a test that checks whether an antibody  against the SARS-CoV-2 virus has been formed in the blood after  SARS-CoV-2 infection or vaccination. SARS-CoV-2 antibody is  detected 1–2 weeks after infection, and antibodies are produced in  more than 90% of infected patients. The duration for the formation of  antibodies differs by individual and by type of antibody. In the case  of IgG, it is at least several months or longer, and the relationship  between antibodies and immunity is being studied. As test methods,  enzyme-linked immunosorbent assay (ELISA), chemiluminescence  immunoassay (CIA), immunochromatographic assay, and neutralizing  antibody assay have been developed and used. The target antibody to be  detected differs depending on the type of recombinant antigen and the  type of secondary antibody in reagents. Many kinds of commercialized  SARS-CoV-2 antibody assays are currently being developed, and  the S (spike) protein, N (nucleocapsid) protein, S1 or RBD (receptor  binding domain) part of the S protein, and a mixture of these antigens  are used as recombinant antigens of reagents. IgG, IgM, IgA, or total  immunoglobulin antibodies in patients’ blood that react with these  reagent antigens are detected. In this review, the types and performance  of SARS-CoV-2 antibody tests and the guidelines for COVID-19  antibody tests published domestically and abroad were investigated.Antibody test,COVID-19,Guideline,SARS-CoV-2

1. Chen N, Zhou M, Dong X, et al., 2020, Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. Lancet, 395: 507–513.2. Mousavizadeh L, Ghasemi S, 2021, Genotype and Phenotype of COVID-19: Their Roles in Pathogenesis. J Microbiol Immunol Infect, 54: 159–163.3. Infantino M, Damiani A, Gobbi FL, et al., 2020, Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. Isr Med Assoc J, 22: 203–210.4. Carter LJ, Garner LV, Smoot JW, et al., 2020, Assay Techniques and Test Development for COVID-19 Diagnosis. ACS Cent Sci, 6: 591–605.5. Deeks JJ, Dinnes J, Takwoingi Y, et al., 2020, Antibody Tests for Identification of Current and Past Infection with SARS-CoV-2. Cochrane Database Syst Rev, 6: CD013652.6. Post N, Eddy D, Huntley C, et al., 2020, Antibody Response to SARS-CoV-2 Infection in Humans: A Systematic Review. PLoS One, 15: e0244126.7. Centers for Disease Control and Prevention (CDC). Interim Guidelines for COVID-19 Antibody Testing. Viewed 30 March 2021, https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.8. Centers for Disease Control and Prevention (CDC). EUA Authorized Serology Test Performance. Viewed 30 March 2021, https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-useauthorizations-medical-devices/eua-authorized-serology-test-performance.9. Government of Canada. COVID-19 Serological Testing Devices: Notice on Sensitivity and Specificity Values. Viewed 30 March 2021, https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/testing/serological/notice-sensitivity-specificity-values.html.10. COVID-19 Laboratory Response Task Force of Korean Society for Laboratory Medicine. Guidelines for the Laboratory Diagnosis of COVID-19 in Korea, 4th ed. 2020, Bureau of Infectious Disease Diagnosis Control of Korea Disease Control and Prevention Agency, Korea.11. Infectious Diseases Society of America (IDSA). IDSA Guidelines on the Diagnosis of COVID-19: Serologic Testing. Viewed 30 March 2021, https://www.idsociety.org/practice-guideline/covid-19-guidelineserology/.12. World Health Organization (WHO). Diagnostic Testing for SARS-CoV-2: Interim Guidance, 11 September 2020. Viewed 31 March 2021, https://apps.who.int/iris/handle/10665/334254.13. De Gruyter. IFCC Interim Guidelines on Serological Testing of Antibodies Against SARS-CoV-2. Viewed 30 March 2021, https://www.degruyter.com/document/doi/10.1515/cclm-2020-1413/html.14. Bailey D, Konforte D, Barakauskas VE, et al., 2020, Canadian Society of Clinical Chemists (CSCC) Interim Consensus Guidance for Testing and Reporting of SARS-CoV-2 Serology. Clin Biochem, 86: 1–7.